Chlamydia trachomatis

Chlamydia Trachomatis and Neisseria Gonorrhoeae Tests Market Forecast to Surge Through 2033 Amid Increasing Diagnostic Demand - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 8, 2024
Health, Infectious Diseases, Infection, ELISA, Chlamydia trachomatis, STI, Naʽat, Neisseria gonorrhoeae, COVID-19, Woman, Vaccine

The "Chlamydia Trachomatis and Neisseria Gonorrhoeae Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chlamydia Trachomatis and Neisseria Gonorrhoeae Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Chlamydia Trachomatis and Neisseria Gonorrhoeae tests is set to embark on a significant growth trajectory from 2020 extending through 2033.
  • With women and young adults between 15-24 years witnessing the most common occurrences, the tests market is experiencing a substantial uptick in demand.
  • Empowered by substantive insights and high-level analytics, the market for Chlamydia Trachomatis and Neisseria Gonorrhoeae tests underscores an optimistic outlook fueled by technological advancements and a deep-seated understanding of the clinical requirements.

Applied BioCode Announces the Launch of the STI + Resistance Panel Assay for Research Use Only

Retrieved on: 
Monday, April 15, 2024
Health, Medical Devices, Infectious Diseases, Genetics, Research, Science, Biotechnology, RUO, Chlamydia trachomatis, Neisseria gonorrhoeae, Laboratory, Trichomonas vaginalis, Collection, STI, DNA, SNP, Mycoplasma genitalium, Vaccine

Applied BioCode Inc., a pioneer in molecular diagnostics, proudly announces the launch of its latest innovation, the BioCode® STI + Resistance Panel (RUO).

Key Points: 
  • Applied BioCode Inc., a pioneer in molecular diagnostics, proudly announces the launch of its latest innovation, the BioCode® STI + Resistance Panel (RUO).
  • The panel is exclusively intended for research purposes and is not intended for diagnostic procedures.
  • Engineered with precision for seamless integration with the BioCode® MDx-3000 automated system, it delivers timely test results approximately 4 hours post-DNA extraction.
  • “We are thrilled to announce the release of the STI + Resistance Panel for research use under our new product strategy.

SCOUT RECEIVES FUNDING FROM CARB-X TO DEVELOP A LOW-COST POINT-OF-CARE AND HOME DIAGNOSTIC FOR GONORRHEA AND CHLAMYDIA

Retrieved on: 
Thursday, April 18, 2024
Chlamydia trachomatis, FDA, Mortality, Administration, Pelvic inflammatory disease, Malaria, Death, Doctor of Philosophy, Vaccine, Development, Point-of-care testing, PHAC, Diagnosis, Gonorrhea, Novo Nordisk Foundation, Prevalence, HHS, Vertical loop, Neonatal sepsis, Infertility, OTC, Public Health Agency, Entrepreneurship, Infection, Urine, Neisseria gonorrhoeae, Patient, Ng, CARB-X, NIH, Education, BMBF, STI, Therapy, Disease, Bangladesh Technical Education Board, SARS-CoV-2, HIV/AIDS, Social work, NIAID, Bill, Physician

BOSTON, April 18, 2024 /PRNewswire/ -- Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award up to US$1 million to diagnostics and health tech company Scout to demonstrate proof-of-concept and feasibility ahead of development of a new point-of-care test – STI Scout. The test will detect and differentiate between Neisseria gonorrhoeae (Ng) and Chlamydia trachomatis (Ct). STI Scout is quick and inexpensive, with a turnaround time of 30 minutes and costs anticipated to be less than half of other options.

Key Points: 
  • STI Scout is quick and inexpensive, with a turnaround time of 30 minutes and costs anticipated to be less than half of other options.
  • Additionally, STI Scout can use either first void urine or vaginal swabs, and future tests will be able to guide therapy for gonorrhea treatment based on antibiotic susceptibility.
  • STI Scout uses the Scout Hub to run and the Scout Connect mobile app, which provides instructions, tracks results, and eventually will allow patients to connect digitally to a healthcare provider.
  • Scout's diagnostic is the second diagnostic and ninth project to receive a CARB-X award as part of the 2022-2023 funding call .

QIAGEN receives FDA clearance of NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 Molecular Systems

Retrieved on: 
Monday, January 8, 2024
Dicarboxylic acid, Food, FDA, QGEN, QIAGEN, Real-time polymerase chain reaction, Infection, DNA, PCR, Genetically modified bacteria, STI, Chlamydia trachomatis, Neisseria gonorrhoeae, Diagnosis, Senior

The majority of these infections are asymptomatic and generally curable with existing single-dose regimens of antibiotics.

Key Points: 
  • The majority of these infections are asymptomatic and generally curable with existing single-dose regimens of antibiotics.
  • This FDA clearance supports the test menu expansion for NeuMoDx Molecular Systems in the U.S.
  • The systems extract DNA to isolate the target nucleic acids and then conduct a real-time polymerase chain reaction (RT-PCR).
  • For more information about the NeuMoDx assay menu, please visit https://go.qiagen.com/neumodx

GeneProof Announces Expansion of its IVDR-Certified PCR Portfolio

Retrieved on: 
Tuesday, October 3, 2023
Ureaplasma urealyticum, CT, IVDR, Urinary tract infection, Workflow, CP, Infection, Neisseria gonorrhoeae, Chlamydia trachomatis, Real-time, Quality management system, Mycoplasma genitalium, Mycoplasma hominis, NG, Canine vector-borne disease, Diagnosis, PCR, Chlamydia pneumoniae, Medical device, Telecommunications, Ureaplasma, EU, Mycoplasma, Chlamydia

BRNO, Czech Republic, Oct. 3, 2023 /PRNewswire/ -- GeneProof, a leader in molecular diagnostics, today announced the addition of six new IVDR-certified PCR kits to its expansive portfolio.

Key Points: 
  • BRNO, Czech Republic, Oct. 3, 2023 /PRNewswire/ -- GeneProof, a leader in molecular diagnostics, today announced the addition of six new IVDR-certified PCR kits to its expansive portfolio.
  • This comes as a testament to the company's dedication to delivering its entire portfolio of approximately 80 products as IVDR compliant by 2027.
  • Currently, 27 products are IVDR cleared, with 16 that are Notified Body certified in class C and B.
  • GeneProof was among the first to obtain the EU Certificate for Quality Management System under the new Regulation (EU) 2017/746 IVDR.

Aspira Women’s Health Announces Dr. Jody Berry as New Chief Scientific Officer

Retrieved on: 
Monday, September 11, 2023
Department of Medical Microbiology (Schering AG), Abstract, Pelvic inflammatory disease, Bachelor of Science, University, Apotex, Medical microbiology, HIV, Cangene, HIV-1, Head, Monoclonal antibody, Public Health Agency of Canada, COVID-19, Woman, CIHR, Infection, Research, Lehigh University, American Biological Safety Association, National Microbiology Laboratory, University of Manitoba, Government, Immunochemistry, Chlamydia trachomatis, Philosophy, Outline, Gynaecology, Blood, Scripps Research, Protein engineering, R, Public Health Agency, G.H. Raisoni Department of Microbiology and Biotechnology, University Arena (Western Michigan University), Vaccine, Science, Chlamydia, Molecular biology, Aspira

AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has named Jody Berry, Ph.D. as its new Chief Scientific Officer.

Key Points: 
  • AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has named Jody Berry, Ph.D. as its new Chief Scientific Officer.
  • Dr. Berry is a seasoned scientific leader with over two decades of commercial, government and academic experience.
  • Jody is a dynamic leader with decades of experience launching disruptive products and building effective research and development teams,” said Nicole Sandford, Chief Executive Officer of Aspira.
  • Dr. Berry is author or co-author on over 100 peer-reviewed published journal articles, abstracts, scientific posters, and monographs.

New Research Shows Promising Possibilities for At-Home Testing to Detect Sexually Transmitted Infections

Retrieved on: 
Tuesday, July 25, 2023
Vagina, Laboratory, Kaiser Permanente, Human papillomavirus infection, STI, Urine, Infection, Los Angeles County Department of Health Services, Research, Temperature, Neisseria gonorrhoeae, Doctor of Philosophy, Centers for Disease Control and Prevention, Chlamydia trachomatis, Public health, Rectum, Cervical cancer, Los Angeles County Department of Public Health, Physician, HPV, Patient, Throat, Birth control, Mineral oil, Neisseria, Chlamydia

ANAHEIM, Calif., July 25, 2023 /PRNewswire/ -- Self-collected tests performed similarly to provider-collected tests for detecting common sexually transmitted infections (STIs), according to research presented today at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo. These findings could enable discreet new testing options that expand access to screening.

Key Points: 
  • ANAHEIM, Calif., July 25, 2023 /PRNewswire/ -- Self-collected tests performed similarly to provider-collected tests for detecting common sexually transmitted infections (STIs), according to research presented today at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo.
  • However, more research is needed to establish the reliability of self-collected tests.
  • For 15 study participants, the researchers evaluated 5 self-collected swabs to assess variability in swabs taken from the same individual.
  • The researchers were motivated to increase inclusivity and access to STI testing by exploring additional options for self-collection and home testing.

Microbix Presents Results of STI Test Controls at AACC

Retrieved on: 
Monday, July 24, 2023
CT, AACC, STI, Trichomonas vaginalis, Abbott, Vertically transmitted infection, QAP (Colombia), Emerging, PCR, Point-of-care testing, Infection, Neisseria gonorrhoeae, Mycoplasma, Chlamydia trachomatis, BD, Assay, RUO, Gertrude Pocte Geddes Willis, American Association for Clinical Chemistry, NG, Mycoplasma genitalium, OTCQX, IVD, TSX, Poster, Medical imaging, Chlamydia, Trichomonas

At AACC, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.

Key Points: 
  • At AACC, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.
  • Microbix will thereby showcase its ever-growing portfolio of QAPs that help ensure the accuracy of antigen and molecular (i.e., “PCR”) tests and their workflows.
  • Microbix therefore developed a whole-workflow multiplex STI QAP desiccated on a Copan FLOQSwab® that is stable at 2-30°C and contains inactive whole-genome target pathogens.
  • We’re pleased to be offering Microbix QAPs to support clinically-important STI testing – as tools for validation, verification, and training, as external quality assessment samples, and as in-kit controls.”

Birmingham spinout to develop 20-minute test following surge in sexually transmitted infections

Retrieved on: 
Thursday, June 8, 2023
Infection, Linearity, National Institute for Health and Care Research, UK Health Security Agency, DNA, University, STI, MSM, Neisseria, Woman, Multimedia, Gonorrhea, University of Birmingham, Chlamydia trachomatis, Patient, Security agency, NIHR, World Health Organization, Vertically transmitted infection, Diagnosis, WHO, WSW, Birth control, Vaccine, Chlamydia

Brendan Farrell, Chairman of Linear Diagnostics, said: "For STIs, the rapidity of the testing procedure is key, as patients prefer to get test results quickly and start treatment immediately.

Key Points: 
  • Brendan Farrell, Chairman of Linear Diagnostics, said: "For STIs, the rapidity of the testing procedure is key, as patients prefer to get test results quickly and start treatment immediately.
  • Its work brings people from across the world to Birmingham, including researchers, teachers and more than 8,000 international students from over 150 countries.
  • The World Health Organization has noted the rapid increase in multi-drug resistant gonorrhoea, with all confirmed treatment failures except one being pharyngeal infections affecting the throat.
  • The UK Health Security Agency warned this week of a surge in gonorrhoea cases, with a 50% increase between 2021 and 2022.

Birmingham spinout to develop 20-minute test following surge in sexually transmitted infections

Retrieved on: 
Thursday, June 8, 2023
Infection, Linearity, National Institute for Health and Care Research, UK Health Security Agency, DNA, University, STI, MSM, Neisseria, Woman, Gonorrhea, University of Birmingham, Chlamydia trachomatis, Patient, Security agency, NIHR, World Health Organization, Vertically transmitted infection, Diagnosis, WHO, WSW, Vaccine, Chlamydia

The University of Birmingham is ranked amongst the world's top 100 institutions.

Key Points: 
  • The University of Birmingham is ranked amongst the world's top 100 institutions.
  • Its work brings people from across the world to Birmingham, including researchers, teachers and more than 8,000 international students from over 150 countries.
  • The World Health Organization has noted the rapid increase in multi-drug resistant gonorrhoea, with all confirmed treatment failures except one being pharyngeal infections affecting the throat.
  • The UK Health Security Agency warned this week of a surge in gonorrhoea cases, with a 50% increase between 2021 and 2022.